1Truelove SC, WittslJ. Corlisonein ulcerative colitis. Reporl on therapeutic trial. Br Med J, 1955,2:1041-1048.
2Stange EF, Travis SPL, Vermeire S, et al. European evidence based Consensus on the diagnosis and management of ulcerative colitis: Definilions and diagnosis. J Crohn's Colitis, 2008,2:1- 23.
3Powell-Tuck J, Bown RL, I.ennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Stand J Gastroenterol. 1978, 13 : 833-837.
4Seo M, Okada M. Yao T, et al. An index of disease activity in patients with ulcerative colitis. AmJ Gastroenterol, 1992, 87:971-976.
5Schroeder KW, Tremaine WJ, llstrup DM. Coated oral 5 aminosalicylic acid therapy for mildly to moderately active ulcerative colilis. A randomized study. N Engl J Med, 1987, 317:1625- 1629.
6Baron JH, Connell AM, I.ennard-Jones JE. Variation between observers in describing mucosa/ appearances in proctocolitis. Br Med J, 196,1,1:89-92.
7SatsangiJ, Silvcrberg MS, Vermeire S, el al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Out, 2006,55:719- 753.
8Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut, 2000,47:404-409.
9Guyatt G. Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflantlnatory bowel disease. Gastroenterology, 1989,96:804-810.
10Jowett SL, Seal CJ, Barton JR, ct al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in Am J Gastroenterol, 2001, 96:2921 -2928.
